NVS Novartis AG stock chart & analysis
Conviction 45HealthcareScan · Fri, Nov 6, 2026Novartis AG (NVS) closed at $162.55 (+0.38%) on Nov 6, 2026. Price is above its 50-day and above its 200-day moving average. RSI(14) 65, RS Rating 87, -4.6% from its 52-week high, +18.0% year to date. Sector: Healthcare · Drug Manufacturers - General.
NVS technical analysis
Trend
NVS's moving averages are mixed — no clean uptrend or downtrend. It closed 9.3% above the 50-day ($148.83) and 6.8% above the 200-day ($152.25). ADX(14) at 27 points to a strong, established trend. It meets 6 of 8 trend-template criteria.
Momentum
RSI(14) is 65, in the bullish half of its range. The MACD histogram is positive. Its RS Rating of 87 puts its weighted 12-month performance ahead of about 87% of the US market, and its RS line is at a new high.
Volume and volatility
Volume on the latest session ran 0.9× its 20-day average. It trades about $325.4M a day on average. ATR(14) is $3.42, 2.1% of price — its typical daily range. On-balance volume is trending up. Chaikin Money Flow (0.08) shows accumulation.
Key levels
The chart pattern's support is $140.81 and its resistance $160.58. The 52-week range is $123.24 to $170.46; price is 4.6% below the high and 32.0% above the low. The VWAP anchored at the 52-week high is $151.76, below price.
Performance
NVS returned +1.1% (1 week), +13.6% (1 month), +3.7% (3 months), +11.4% (6 months), +29.6% (1 year), +18.0% (year to date).
About Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Drug Manufacturers - General · Listed 1996 · 75,267 employees
Congress activity
Disclosed STOCK Act trades in NVS · 10 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Kevin Hern house · R · OK · traded 2026-08-27 | Sell | $15K–$50K | 2026-08-27 | 2026-09-25 | |
 Alan Armstrong senate · R · OK · traded 2026-03-31 | Buy | $1K–$15K | 2026-03-31 | 2026-07-21 | |
Alan Armstrong senate · R · OK · traded 2026-03-30 | Buy | $15K–$50K | 2026-03-30 | 2026-07-21 | |
 Lisa McClain house · MI · traded 2025-10-30 | Buy | $1K–$15K | 2025-10-30 | 2025-11-01 | |
Lisa McClain house · R · MI · traded 2025-09-25 | Sell | $1K–$15K | 2025-09-25 | 2025-10-22 | |
Lisa McClain house · R · MI · traded 2025-09-11 | Buy | $1K–$15K | 2025-09-11 | 2025-10-22 | |
Lisa McClain house · R · MI · traded 2025-07-22 | Sell | $1K–$15K | 2025-07-22 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-06-10 | Sell | $1K–$15K | 2025-06-10 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-06-17 | Buy | $1K–$15K | 2025-06-17 | 2025-08-13 | |
Lisa McClain house · R · MI · traded 2025-06-11 | Buy | $1K–$15K | 2025-06-11 | 2025-08-13 |
SEC filings
EDGAR filings in NVS · 8 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.